Global Genome Editing Market Size, Share, Growth Analysis, By Technology(CRISPR, TALEN), By Delivery Method(Ex-vivo, In-vivo), By Mode(Contract, In-house), By End Use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes) - Industry Forecast 2022-2028

The Global Genome Editing Market is segmented based on Technology, Delivery Method, Mode, End-use, Application, and Region. Based on Technology it is categorized into CRISPR, TALEN, ZFN, Antisense, and Other Technologies. Based on the Delivery Method it is categorized into Ex-vivo and In-vivo. Based on Mode it is categorized into Contract, In-house. Based on End-use it is categorized into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Based on the Region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Analysis by Technology

In 2021, the CRISPR/Cas9 segment dominated the market, accounting for 40.2% of revenue. With its technical advantages, this technique has revolutionized the genome manipulation space. The benefits include targeted gene disruption, guide RNA-specific recovery, and regulation. These benefits have accelerated the adoption of CRISPR/Cas9 technology in a relatively broad range of applications.

CRISPR clinical applications have found widespread applications. This is evidenced by the growing number of ongoing clinical trials using gene-editing techniques to treat a variety of diseases such as cancer, AIDS, and genetic diseases. Apart from human health, this technology is increasingly being used in agriculture and animal breeding.

Analysis by End-User

In 2021, the biotechnology and pharmaceutical companies segment dominated the market, accounting for 48.4% of revenue. The rising number of research activities for novel therapeutic development is a major contributor to segment revenue generation. Furthermore, global pharmaceutical companies are working with emerging companies to develop new technologies. For instance, in April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc., signed a strategic collaboration and licensing agreement to address rare and serious diseases. CANbridge Pharmaceuticals, Inc. obtained rights to the latter company's gene-editing platforms as a result of this agreement. Similarly, in October 2020, Scribe Therapeutics and Biogen announced a collaboration to develop CRISPR-based genetic medicines for neurological diseases such as Amyotrophic Lateral Sclerosis.

On the other hand, Government research and academic institutes, are expected to grow rapidly over the forecast period as gene-editing technologies become more widely used in university-level projects. The active participation of research institutes contributes to the segment's growth. For instance, Baylor College of Medicine, Rice University, and the Whitehead Institute are all actively involved in efforts to advance genome editing.

North America dominated the genome editing market in 2021, accounting for 38.4% of total revenue. The dominance of the Genome Editing Market in the region is due to the availability of strong research, as well as a commercial base for advanced therapeutic development, as well as a large number of clinical studies being undertaken for gene and stem cell therapies in the region. On the other hand, the market in the Asia Pacific is expected to expand at a rapid rate over the projected period. China unveiled its 10 most significant agricultural breakthroughs in November 2020, one of which was gene-editing technology, demonstrating strong Genome Editing Market penetration.

Driver

• Governments in various countries around the world have made significant investments in the field of genomics in recent years, which has played a significant role in the development of new technologies in genome editing. Furthermore, the availability of government funding has enabled academic and government institutes to conduct in-depth genome editing/engineering research. For instance, in March 2020, the Ministry of Innovation, Science, and Industry (Science) announced a USD 15 million grant to Genome Canada to support 11 genomic research projects in the health, agriculture, and environment sectors. Provincial governments, businesses, and research partners will also contribute to these projects, with a total investment of USD 29.7 million. Ovarian and cervical cancer research is among the projects. The number of genomics research projects has increased significantly as a result of significant government investments in genomics. As a result, the genome editing market is expected to grow during the forecast period.
• Easy to use CRISPR/CAS9 will  propel the growth of the market. This technological segment is simple , inexpensive compared to other genome editing methods.This technology can be used in treatment of cancer through gene editing technology.

Restraint

• CRISPR-Cas9's off-target effects are a major concern. Though since Cas9 induces double-stranded breaks, any off-target nuclease activity can result in mutations in these genes, possibly causing oncogenesis. CRISPR-Cas9 is capable to withstand one to three mismatches in its target, which can result in off-target nuclease activity. Furthermore, the high frequency of off-target activity (50%)—mutations at sites other than the intended on-target site—is a major area of concern. for instance, CRISPR can target the tumor suppressor genes or activate the cancer-causing gene. Many companies planning clinical trials have encountered difficulties as a result of this unfavorable effect. Clinical trials have been halted, and regulatory authorities are urging additional research to improve the safety of this method.

• The advanced functionalities and features of Genomic instruments are a significant reason for its premium pricing. Its pricing ranges between USD 10-20 million. The small and medium sized laboratories and Pharmaceuticals companies cannot afford the equipment at such high cost. which can be the major restraint in the expansion of the market.

The market's various competitors are challenged to provide innovative offerings that enable communication in addressing changing technologies, business practices, and security needs. Partnerships, strategic mergers, and acquisitions are expected to be the most effective ways for industry players to gain quick access to emerging markets while also improving technological capabilities. Custom vectors for cell line editing and engineering are provided by well-established companies such as Merck KGaA and Thermo Fisher Scientific. Such services are anticipated to grow in the coming years, fueling revenue growth. Contract manufacturers would benefit from the rapidly increasing demand from gene therapy Genome Editing Market players.

Top Players Company Profiles

• Thermo Fisher Scientific (US)
• Merck KGaA (Germany)
• GenScript (China)
• Sangamo Therapeutics (US)
• Lonza (Switzerland)
• Editas Medicine (US)
• CRISPR Therapeutics AG (Switzerland)
• Tecan Life Sciences (Switzerland)
• Precision Biosciences (US)
• Agilent Technologies (US)

Recent Developments

• In May 2022, CRISPR-Combo is a method developed by scientists at the University of Maryland College of Agriculture and Natural Resources to edit multiple genes in plants while simultaneously changing the expression of other genes. This new tool will allow genetic engineering combinations to work together to improve crop functionality and breeding.
• In May 2022, GenScript Introduces GMP Single-Strand and Double-Strand DNA Services to Aid in the Development of Gene and Cell Therapy.

• In January 2022,The researchers and developers working on the plant in England will have easier access to genetic technology such as Gene editing.

• In February 2022, Integrated DNA Technologies unveiled Alt-R    HDR Donor Blocks, an improved solution for increasing homology-directed repair (HDR) rates. Alt-R HDR Donor Blocks are the latest addition to IDT’s complete portfolio of Alt-R CRISPR genome editing solutions.

• In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).

• In April 2021, Researchers at Harvard's Wyss Institute for Biologically Inspired Engineering created Retron Library Recombineering (RLR), a new gene-editing tool that allowed for the simultaneous execution of millions of genetic experiments, resulting in higher editing rates.

• In March 2021, A team of Nanyang Technological University researchers created a diagnostic test called VaNGuard (Variant Nucleotide Guard) that is based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, which will increase the use of CRISPR genome editing technology in diagnostics.

• In November 2020, Eli Lilly and Company collaborated with Precision BioSciences, Inc. to develop potential in-vivo therapeutics for genetic disorders using the latter company's proprietary ARCUS genome editing platform. Such collaborations have heightened market competition, resulting in organic revenue growth. 

• The COVID-19 pandemic has prompted major pharmaceutical and biotechnology firms, as well as players in the genomic market, to invest in vaccine research and development. The increased demand for vaccines and antiviral candidates has pushed genome editing/engineering technologies to the forefront, these factors are expected to drive the Genome Editing Market in the upcoming years.
• In COVID-19 outbreaks, molecular biology tools such as CRISPR-Cas12/13-based SHERLOCK, DETECTOR, CARVER and PAC-MAN, ASO, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing therapies proved critical when compared to conventional diagnostic or treatment methods. These tools served as new generation diagnosis and treatment methods, ranging from faster and easier diagnosis to more targeted virus detection and killing, such factors have become a key factor and are expected to drive the Genome Editing Market over the forecast year.

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. SQ identified the key dominating segments of the Genome Editing Market by offerings and verticals.

According to our analysis, the personalized medicine Genome Editing Market is expected to provide opportunities for players in the genome editing market. Personalized medicine allows doctors to quickly identify a patient's specific requirements and then prescribe medications and treatments to meet those needs. Personalized medicine is becoming more popular around the world due to its potential for cost savings, improved patient compliance, early disease detection, and therapy optimization.

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.